Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study

Table 7 Comparison between patients with COVID-19 who received or did not receive previous direct-acting antiviral therapy

		Did not receive previous DAA (n = 108)	Received previous DAA (n = 17)	P value
COVID-19 severity	Moderate	72 (66.7%)	14 (82.4%)	0.26
	Severe	36 (33.3%)	3 (17.6%)
Admission zone	ICU	22 (20.4%)	2 (11.8%)	0.52
	Intermediate care	6 (5.6%)	0 (0.0%)
	Ward	80 (74.1%)	15 (88.2%)
Vital status	Alive	73 (67.6%)	12 (70.6%)	1
	Dead	35 (32.4%)	5 (29.4%)
Total bilirubin (mg/dL)		1.00 (1-20)	1.30 (1-6)	0.84
Direct bilirubin (mg/dL)		0.9 (0.2-15.6)	0.9 (0.1-2.7)	0.93
Serum albumin (g/dL)		3.1 (1.7-5)	3.15 (2.4-3.8)	0.45
Alanine transaminase (U/L)		41.5 (13-324)	49 (18-175)	0.54
Aspartate transaminase (U/L)		46.5 (10- 549)	53 (16-415)	0.42

DAA: Direct-acting antiviral; COVID-19: coronavirus disease 2019; ICU: Intensive care unit.